Organisation paid for research Program year 2025 Source: CMS Open Payments

The West Clinic

Neither a doctor nor a teaching hospital

Research payments

$6,717,676

168 payments

Through program year 2025, The West Clinic is reported as receiving $6,717,676 in research payments, across 168 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$132,798	59
2024	Research	$1,153,713	11
2023	Research	$1,701,240	14
2022	Research	$2,061,211	27
2021	Research	$651,331	22
2020	Research	$499,046	25
2019	Research	$518,336	10

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $3,950,300 55 payments
E.R. Squibb & Sons, L.L.C. $1,803,546 25 payments
Novartis Pharmaceuticals Corporation $680,931 2 payments
Eli Lilly and Company $241,292 14 payments
Novocure GmbH $18,250 4 payments
Novocure Inc. $5,850 2 payments
Mirati Therapeutics, Inc. $5,611 1 payment
Celgene Corporation $2,310 1 payment
Spectrum Pharmaceuticals Inc. $2,186 1 payment
Daiichi Sankyo Inc. $2,005 53 payments

Studies the money was for Research payments · program years 2019–2025

214360 $2,295,941 13 payments
0000000000000000000000000000000000000000000000000000000000000000214360 $1,161,257 15 payments
Ribociclib Standard Endocrine Therapy in Patients With HR Her2 Early BC at High Amp Intermediate Risk for Recurrence $680,931 2 payments
Phase I II FIH Monotherapy Nivo Combination $407,556 2 payments
Study name not reported $401,982 7 payments
Phase I II Other I-O Triplet lag3 nivo ipi vs lag3 nivo IDO $318,553 1 payment
Phase I II TIM3 FIH Monotherapy Nivo Combination in advanced solid tumors $309,630 2 payments
PhI II Other I-O Triplet lag3 nivo ipi vs lag3 nivo IDO $206,522 2 payments
Phase I II FIH Anti-NKG2A Monotherapy Nivo Combination in advanced solid tumors $198,317 1 payment
Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $159,954 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.